fda warning letter compounding semaglutide october 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 Navigating Compounded Semaglutide: What Health

Description

That's a genuinely significant development in obesity medicine, and it's the reason GLP-1 therapy has moved from "cosmetic weight loss medication" to "cardiometabolic treatment" in clinical guidelines

Sleep Apnea and Kidney Disease Separate ongoing TRIUMPH Phase 3 trials are evaluating retatrutide in patients with moderate-to-severe obstructive sleep apnea and in adults with chronic kidney disease and obesity

It is in the same family of drugs (incretin-based pharmacotherapy for weight and metabolic disease) but it acts on three receptors rather than one

Earlier litigation involving Victoza and other incretin mimetics included claims that the drug was linked to pancreatic cancer, pancreatitis, and other serious conditions, and some of these claims were consolidated in federal court, though many were dismissed or resolved years ago